11:15 AM EDT, 07/15/2025 (MT Newswires) -- Bausch + Lomb ( BLCO ) Q2 earnings are expected to benefit from foreign exchange tailwinds and robust momentum in its prescription dry eye disease portfolio, RBC Capital Markets said in a Monday research report.

The brokerage said it expects FX tailwinds of almost $20 million to Q2 revenue and nearly $60 million for 2025, based on the strength of many currencies relative to the US dollar.

RBC also raised its Q2 revenue guidance for Bausch's prescription eye drop Miebo to around $81 million from $74 million earlier and $315 million for full-year 2025. For the non-steroid eye drop Xiidra, the brokerage now expects Q2 revenue of $85 million and $345 million for 2025. Total contact lens and consumer revenue in Q2 are expected to be $253 million and $487 million, respectively, the analysts said.

For 2025, RBC said it modelled total revenue of $5.08 billion and adjusted earnings before interest, taxes, depreciation, and amortization of $883 million.

Strong adoption trends for the company's reintroduced enVista intraocular lenses in June were also observed within weeks of their return to the market, according to the note.

RBC reiterated its outperform rating on the stock with a price target of $17 per share. Bausch is scheduled to report Q2 earnings on July 30

Price: 13.72, Change: +0.04, Percent Change: +0.26